Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 31;3(5):335-342.
doi: 10.35772/ghm.2021.01079.

Seamless support from screening to anti-HCV treatment and HCC/ decompensated cirrhosis: Subsidy programs for HCV elimination

Hiroko Setoyama  1   2 , Yasuhito Tanaka  1 , Tatsuya Kanto  2
Affiliations
Review

Seamless support from screening to anti-HCV treatment and HCC/ decompensated cirrhosis: Subsidy programs for HCV elimination

Hiroko Setoyama et al. Glob Health Med. .

Abstract

Viral hepatitis poses a major public health problem in Japan. Chronic viral hepatitis is a progressive liver disease that eventually develops into liver cirrhosis and liver cancer. Since nucleic acid analog therapy for hepatitis B and interferon-free therapy for hepatitis C have made it possible to control the disease status or eliminate the viruses, it is very important that more people receive hepatitis virus tests to confirm the presence of infection at an early stage, and that patients with hepatitis detected by the tests receive appropriate medical care. Currently, the government of Japan is implementing comprehensive measures for hepatitis control based on five key strategies. Moreover, the goal listed in the Basic Guidelines on Hepatitis Measures is to reduce the frequency of progression of hepatitis to cirrhosis or liver cancer through a scheme consisting of testing people for hepatitis, getting those who test positive to visit a medical institution and receive treatment, and providing appropriate and high-quality hepatitis care through specialized medical institutions and regional core centers for the management of liver disease. To achieve the goal, various subsidy programs including an expense subsidy system for hepatitis treatment have been implemented in Japan. It is important for healthcare professionals to have sufficient knowledge of public support for efficient hepatitis C virus (HCV)-related liver disease detection and care.

Keywords: Basic Guidelines on Hepatitis Measures; hepatitis; public support; subsidy program; viral hepatitis policy.

PubMed Disclaimer

Conflict of interest statement

Tatsuya Kanto receives lecture fees from Gilead Sciences and Abbvie. Yasuhito Tanaka is currently conducting research sponsored by Fujifilim Corp., Janssen Pharmaceutical K.K, Gilead Sciences, GlaxoSmithKline Pharmaceuticals Ltd, and Stanford University. Lecture fees are as follows: Fujirebio Inc., Abbvie. and Gilead Sciences. Scholarship Donations from Abbvie. The other authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Seamless public support from screening to anti-HCV treatment and HCC/decompensated cirrhosis. HBsAg: hepatitis B surface antigen, HCC: hepatocellular carcinoma, HCV: hepatitis C virus, HCVAb: hepatitis C antibody.
Figure 2.
Figure 2.
Development of the number of people who received HCV screening tests at local governments. The total number of the Project for Promoting Testing for Specified Infectious Diseases and the Health Promotion Project. HCV: hepatitis C virus.
Figure 3.
Figure 3.
Efforts for raising public awareness of the hepatitis screening tests of the local governments. (A) The means used to make screening tests widely-known in Prefectures, Cities with public health centers and special wards. (B) The means used to make screening tests widely-known in municipalities.
Figure 4.
Figure 4.
Development of the number of issued hepatitis treatment beneficiary certificates. In the roughly 5 years since interferon-free therapy was approved in Japan for chronic hepatitis C, the number of certificates regarding IFN-free therapy have decreased. IFN: interferon, NA: nucleic acid analogue.
Figure 5.
Figure 5.
The image of project to promote research on treatment of liver cancer and severe cirrhosis. *Maximum amount of high-cost medical expense benefit. **Treatment should be done at designated medical institutions to receive support for treatment costs.
See this image and copyright information in PMC

References

    1. Ministry of Health, Labour and Welfare. Promotion of comprehensive measures for hepatitis control - What is hepatitis -. http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/hepatitis_about.... (accessed June 10, 2021). (in Japanese) .
    1. Oza N, Isoda H, Ono T, Kanto T. Current activities and future directions of comprehensive hepatitis control measures in Japan: The supportive role of the Hepatitis Information Center in building a solid foundation. Hepatol Res. 2017; 47:487-496. - PubMed
    1. Health, Labour and Welfare Statistics Association. Viral Hepatitis. In:Trends in national health, 2016/2017. Health, Labour and Welfare Statistics Association. Tokyo, Japan, 2016; pp.146-148. (in Japanese)
    1. Kaishima T, Fujii T, Matsuoka T, et al. . Study of the issues of receiving hepatitis screening and the rate of consulting hospitals - The rate of recognized receiving hepatitis screening and that of the unrecognized. Kanzo. 2016; 57:634-648. (in Japanese)
    1. Ministry of Health, Labour and Welfare. The 25th Meeting of the Council for Promotion of Hepatitis Measures. Document 1. https://www.mhlw.go.jp/content/10901000/000719442.pdf (accessed June 10, 2021). (in Japanese) .

LinkOut - more resources